Shang Xiaobin, Fang Yan, Xin Wenqiang, You Hongbo
Department of Orthopaedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
J Inflamm Res. 2022 Apr 21;15:2583-2599. doi: 10.2147/JIR.S359887. eCollection 2022.
Osteoarthritis (OA) is a whole joint disease characterized by synovitis, cartilage destruction, and subchondral bone sclerosis and cyst. Despite decades' study, effective treatment is rare for this chronic disease. Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptosis bodies, are nano-sized vesicles with a cargo containing biologically active agents, such as nucleic acids, lipids, and proteins. As a group of short non-coding RNAs, microRNAs (miRNAs) can be delivered by parental cells secreted EVs. Negatively regulate the target mRNAs at the posttranscriptional level and regulate gene expression in recipient cells without modifying gene sequence. Recently, most studies focused on the function of EVs mediated miRNAs in the pathophysiological process of OA. However, all kinds of EVs specific and OA specific factors might influence the administration of EVs-miRNAs, especially the precise quantitative management. As a result, the flourishing of current research about EVs in the laboratory might not promote the relevant clinical transformation in OA treatment. In this review, we reviewed the present application of EVs-miRNAs in the therapeutic of OA and further analyzed the potential factors that might influence its application. Further progress in the quantitative management of EVs-miRNAs would accelerate the clinical transformation of miRNAs enriched EVs in the OA field.
骨关节炎（OA）是一种全关节疾病，其特征为滑膜炎、软骨破坏以及软骨下骨硬化和囊肿。尽管经过数十年研究，这种慢性病仍鲜有有效治疗方法。细胞外囊泡（EVs），包括外泌体、微囊泡和凋亡小体，是纳米级囊泡，其内含物包含生物活性剂，如核酸、脂质和蛋白质。作为一组短链非编码RNA，微小RNA（miRNAs）可由亲本细胞分泌的EVs递送。在转录后水平对靶mRNA进行负调控，并在不改变基因序列的情况下调节受体细胞中的基因表达。最近，大多数研究聚焦于EVs介导的miRNAs在OA病理生理过程中的作用。然而，各类特定的EVs和OA特异性因子可能会影响EVs-miRNAs的应用，尤其是精确的定量管理。因此，目前实验室中关于EVs的蓬勃研究可能无法推动OA治疗中的相关临床转化。在本综述中，我们回顾了EVs-miRNAs在OA治疗中的当前应用，并进一步分析了可能影响其应用的潜在因素。EVs-miRNAs定量管理方面的进一步进展将加速富含miRNAs的EVs在OA领域的临床转化。
